Literature DB >> 21396984

Animal models relevant to human prostate carcinogenesis underlining the critical implication of prostatic stem/progenitor cells.

Murielle Mimeault1, Surinder K Batra.   

Abstract

Recent development of animal models relevant to human prostate cancer (PC) etiopathogenesis has provided important information on the specific functions provided by key gene products altered during disease initiation and progression to locally invasive, metastatic and hormone-refractory stages. Especially, the characterization of transgenic mouse models has indicated that the inactivation of distinct tumor suppressor proteins such as phosphatase tensin homolog deleted on chromosome 10 (PTEN), Nkx3.1, p27(KIP1), p53 and retinoblastoma (pRb) may cooperate for the malignant transformation of prostatic stem/progenitor cells into PC stem/progenitor cells and tumor development and metastases. Moreover, the sustained activation of diverse oncogenic signaling elements, including epidermal growth factor receptor (EGFR), sonic hedgehog, Wnt/β-catenin, c-Myc, Akt and nuclear factor-kappaB (NF-κB) also may contribute to the acquisition of more aggressive and hormone-refractory phenotypes by PC stem/progenitor cells and their progenies during disease progression. Importantly, it has also been shown that an enrichment of PC stem/progenitor cells expressing stem cell-like markers may occur after androgen deprivation therapy and docetaxel treatment in the transgenic mouse models of PC suggesting the critical implication of these immature PC cells in treatment resistance, tumor re-growth and disease recurrence. Of clinical interest, the molecular targeting of distinct gene products altered in PC cells by using different dietary compounds has also been shown to counteract PC initiation and progression in animal models supporting their potential use as chemopreventive or chemotherapeutic agents for eradicating the total tumor cell mass, improving current anti-hormonal and chemotherapies and preventing disease relapse. 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21396984      PMCID: PMC3276073          DOI: 10.1016/j.bbcan.2011.03.001

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  170 in total

1.  Stemness markers characterize IGR-CaP1, a new cell line derived from primary epithelial prostate cancer.

Authors:  Anne Chauchereau; Nader Al Nakouzi; Catherine Gaudin; Sylvestre Le Moulec; Daniel Compagno; Nathalie Auger; Jean Bénard; Paule Opolon; François Rozet; Pierre Validire; Gaëlle Fromont; Karim Fizazi
Journal:  Exp Cell Res       Date:  2010-10-23       Impact factor: 3.905

2.  EGFR and Her-2 regulate the constitutive activation of NF-kappaB in PC-3 prostate cancer cells.

Authors:  Cécile Le Page; Ismael Hervé Koumakpayi; Laurent Lessard; Anne-Marie Mes-Masson; Fred Saad
Journal:  Prostate       Date:  2005-10-01       Impact factor: 4.104

3.  Reciprocal activation of prostate cancer cells and cancer-associated fibroblasts stimulates epithelial-mesenchymal transition and cancer stemness.

Authors:  Elisa Giannoni; Francesca Bianchini; Lorenzo Masieri; Sergio Serni; Eugenio Torre; Lido Calorini; Paola Chiarugi
Journal:  Cancer Res       Date:  2010-08-10       Impact factor: 12.701

4.  Androgen deprivation and stem cell markers in prostate cancers.

Authors:  Yao Tang; Anne W Hamburger; Linbo Wang; Mohammad Afnan Khan; Arif Hussain
Journal:  Int J Clin Exp Pathol       Date:  2009-11-10

5.  Genomic analysis of prostate cancer stem cells isolated from a highly metastatic cell line.

Authors:  Rebecca A Rowehl; Howard Crawford; Antoine Dufour; Jingfang Ju; Galina I Botchkina
Journal:  Cancer Genomics Proteomics       Date:  2008 Nov-Dec       Impact factor: 4.069

6.  Dietary feeding of dibenzoylmethane inhibits prostate cancer in transgenic adenocarcinoma of the mouse prostate model.

Authors:  Tin Oo Khor; Siwang Yu; Avanthika Barve; Xingpei Hao; Jin-Liern Hong; Wen Lin; Barbara Foster; Mou-Tuan Huang; Harold L Newmark; Ah-Ng Kong
Journal:  Cancer Res       Date:  2009-08-25       Impact factor: 12.701

7.  Stage-specific inhibitory effects and associated mechanisms of silibinin on tumor progression and metastasis in transgenic adenocarcinoma of the mouse prostate model.

Authors:  Komal Raina; Subapriya Rajamanickam; Rana P Singh; Gagan Deep; Manesh Chittezhath; Rajesh Agarwal
Journal:  Cancer Res       Date:  2008-08-15       Impact factor: 12.701

8.  Divergent effects of castration on prostate cancer in TRAMP mice: possible implications for therapy.

Authors:  Yao Tang; Linbo Wang; Olga Goloubeva; Mohammad Afnan Khan; Bin Zhang; Arif Hussain
Journal:  Clin Cancer Res       Date:  2008-05-15       Impact factor: 12.531

9.  In vitro propagation and characterization of neoplastic stem/progenitor-like cells from human prostate cancer tissue.

Authors:  Natalia Guzmán-Ramírez; Maureen Völler; Antoinette Wetterwald; Markus Germann; Neil A Cross; Cyrill A Rentsch; Jack Schalken; George N Thalmann; Marco G Cecchini
Journal:  Prostate       Date:  2009-11-01       Impact factor: 4.104

10.  Decorin suppresses prostate tumor growth through inhibition of epidermal growth factor and androgen receptor pathways.

Authors:  Yunping Hu; Haiguo Sun; Rick T Owens; Jiansheng Wu; Yong Q Chen; Isabelle M Berquin; Donna Perry; Joseph T O'Flaherty; Iris J Edwards
Journal:  Neoplasia       Date:  2009-10       Impact factor: 5.715

View more
  10 in total

1.  Development of animal models underlining mechanistic connections between prostate inflammation and cancer.

Authors:  Murielle Mimeault; Surinder K Batra
Journal:  World J Clin Oncol       Date:  2013-02-10

Review 2.  Frequent gene products and molecular pathways altered in prostate cancer- and metastasis-initiating cells and their progenies and novel promising multitargeted therapies.

Authors:  Murielle Mimeault; Surinder K Batra
Journal:  Mol Med       Date:  2011-05-20       Impact factor: 6.354

Review 3.  Advanced prostate cancer--a case for adjuvant differentiation therapy.

Authors:  Jayant K Rane; Davide Pellacani; Norman J Maitland
Journal:  Nat Rev Urol       Date:  2012-08-14       Impact factor: 14.432

Review 4.  Emergence of zebrafish models in oncology for validating novel anticancer drug targets and nanomaterials.

Authors:  Murielle Mimeault; Surinder K Batra
Journal:  Drug Discov Today       Date:  2012-08-10       Impact factor: 7.851

Review 5.  Gene interference strategies as a new tool for the treatment of prostate cancer.

Authors:  Mariarosaria Boccellino; Concetta Alaia; Gabriella Misso; Alessia Maria Cossu; Gaetano Facchini; Raffaele Piscitelli; Lucio Quagliuolo; Michele Caraglia
Journal:  Endocrine       Date:  2015-06-07       Impact factor: 3.925

6.  Preclinical Remodeling of Human Prostate Cancer through the PTEN/AKT Pathway.

Authors:  Marco A De Velasco; Hirotsugu Uemura
Journal:  Adv Urol       Date:  2012-02-21

7.  Pathobiological implications of the expression of EGFR, pAkt, NF-κB and MIC-1 in prostate cancer stem cells and their progenies.

Authors:  Murielle Mimeault; Sonny L Johansson; Surinder K Batra
Journal:  PLoS One       Date:  2012-02-23       Impact factor: 3.240

8.  Marked improvement of cytotoxic effects induced by docetaxel on highly metastatic and androgen-independent prostate cancer cells by downregulating macrophage inhibitory cytokine-1.

Authors:  M Mimeault; S L Johansson; S K Batra
Journal:  Br J Cancer       Date:  2013-02-28       Impact factor: 7.640

9.  Hypoxia-inducing factors as master regulators of stemness properties and altered metabolism of cancer- and metastasis-initiating cells.

Authors:  Murielle Mimeault; Surinder K Batra
Journal:  J Cell Mol Med       Date:  2013-01-10       Impact factor: 5.310

10.  Generation of transgenic mouse line with prostate-specific expression of codon-improved Cre recombinase.

Authors:  Mayuko Kanayama; Kazuki Nakao; Shigeo Horie; Atsu Aiba
Journal:  Prostate Int       Date:  2018-04-27
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.